Bone marrow and peripheral blood stem cell transplantation for malignancy: a review
Johnson P W M, Simnett S J, Sweetenham J W Morgan G J, Stewart L A
Record ID 31998008905
To assess the relative effectiveness of high-dose myeloablative therapy and progenitor cell transplantation (HDT/PCT) compared with conventional therapy for the treatment of malignancy.
To assess the relative cost of HDT/PCT versus conventional chemotherapy (CC).
To assess the efficacy and cost of bone marrow transplantation (BMT) versus peripheral blood progenitor cells transplantation (PBPCT).
Authors' recommendations: As a whole the review has found no conclusive evidence that HDT/PCT is superior to conventional treatment in terms of survival or PFS. Conversely, it has not demonstrated that it is inferior. Given the overall pattern of results, HDT/PCT appears to be a therapy worthy of further exploration. As few prospective economic analyses were identified it is not possible accurately to determine the comparative cost of HDT/PCT and CC.
Authors' methods: Systematic review
Project Status: Completed
URL for project: http://www.hta.ac.uk/963
Year Published: 1998
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
- Child, Preschool
- Controlled Clinical Trials as Topic
- Costs and Cost Analysis
- Middle Aged
- Treatment Outcome
- Bone Marrow Transplantation
- Breast Neoplasms
- Hematologic Neoplasms
- Hematopoietic Stem Cell Transplantation
- Lung Neoplasms
- Multiple Myeloma
- Ovarian Neoplasms
- Testicular Neoplasms
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: 2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.